Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond the dose: social determinants and treatment intensity in DLBCL.

Leukemia & lymphoma·2026
Same author

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Transplantation and cellular therapy·2026
Same author

Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.

Hematological oncology·2026
Same author

Revisiting KIR Restriction and CD94 Expression in Diagnostic Criteria for NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026

Related Experiment Video

Updated: Mar 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K

Clinical approach to diffuse large B cell lymphoma.

Paolo F Caimi1, Brian T Hill2, Eric D Hsi3

  • 1Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.

Blood Reviews
|September 7, 2016
PubMed
Summary

Diffuse large B cell lymphoma (DLBCL) is a common, heterogeneous cancer. This review covers current understanding and debates in diagnosing, treating, and monitoring DLBCL patients for optimal outcomes.

Keywords:
Autologous stem cell transplantChemotherapyDiffuse large B cell lymphoma (DLBCL)Novel targeted therapy for lymphoma

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.6K

Related Experiment Videos

Last Updated: Mar 15, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.6K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin lymphoma.
  • DLBCL is recognized as a biologically diverse group of diseases, not a single entity.
  • Curative potential exists for many DLBCL patients, underscoring the need for precise management.

Purpose of the Study:

  • To review current consensus and controversial areas in the evaluation of DLBCL.
  • To discuss established and debated therapeutic strategies for DLBCL.
  • To outline best practices for monitoring patients with DLBCL and related subtypes.

Main Methods:

  • Literature review of recent studies and clinical guidelines.
  • Analysis of consensus statements from expert panels.
  • Identification of areas of ongoing clinical and scientific debate.

Main Results:

  • DLBCL heterogeneity impacts diagnostic and therapeutic approaches.
  • Standardized diagnostic and staging evaluations are crucial.
  • Treatment and monitoring strategies require careful consideration of disease subtype and patient factors.

Conclusions:

  • Accurate diagnosis and staging are paramount for effective DLBCL management.
  • Therapeutic decisions should integrate current evidence and address areas of controversy.
  • Ongoing monitoring is essential for assessing treatment response and long-term outcomes in DLBCL.